GENE EDITING 101
All Companies
🇺🇸

Sangamo Therapeutics

Public

Zinc finger pioneers

Sangamo is a pioneer in gene editing, having developed zinc finger nuclease (ZFN) technology before CRISPR existed. They have the longest clinical track record in gene editing, with established safety data from multiple trials.

Founded1995
HQBrisbane, CA
CEOAlexander Hardy
TickerNASDAQ:SGMO
Total Funding$1.5B

Pipeline

Drug / ProgramIndicationPhaseTechnology
GiroctocogeneHemophilia APhase 3AAV Gene Therapy
Isaralgagene civaparvovecFabry DiseasePhase 1/2AAV Gene Therapy
TX200Kidney TransplantPhase 1/2ZFN

Key People

Alexander HardyCEO

Related Articles

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?
Biotech Companies
Market Analysis

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?

A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.

Mar 16, 20266 min read